Skip to main content

Tirosint-Sol News

U.S. Food And Drug Administration Grants Two New Label Changes to Tirosint-SOL (levothyroxine sodium) Oral Solution

PARSIPPANY, N.J.--(BUSINESS WIRE) December 04, 2023 --The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a...

Levothyroxine Infusion Does Not Increase Heart Transplants Versus Saline Infusion

THURSDAY, Nov. 30, 2023 – Intravenous levothyroxine infusion does not result in more hearts being transplanted than saline infusion among hemodynamically unstable brain-dead potential heart donors,...

FDA Medwatch Alert: IBSA Pharma Inc. Issues Voluntary Nationwide Recall of Select Lots of Tirosint®-Sol (levothyroxine sodium) Oral Solution Due to Subpotency

February 01, 2023 – IBSA Pharma Inc. is voluntarily recalling 27 lots of TIROSINT®-SOL (levothyroxine sodium) Oral Solution to the consumer level. This voluntary recall has been initiated ...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Hashimoto's Disease, Underactive Thyroid, Hypothyroidism, TSH Suppression

Tirosint-Sol patient information at Drugs.com